Podcast
Dr. Fizazi discusses potential of darolutamide-based triplet regimen for metastatic hormone-sensitive prostate cancer
Author(s):
“Obviously, patients benefit [from this regimen]. Not only can they enjoy longer life, but also their cancer is pretty much under control for a longer time, which is great,” says Karim Fizazi, MD, PhD
In this episode, Urology Times® Assistant Editor Janelle Hart spoke with Karim Fizazi, MD, PhD, about results from a game-changing study that was presented at the 2022 ASCO Genitourinary Cancers Symposium. The phase 3 ARASENS trial showed that a darolutamide-based triplet regimen improved overall survival in patients with metastatic hormone-sensitive prostate cancer. Fizazi is a medical oncologist and head of the department of cancer medicine at the Institute of Gustave Roussy, and professor of oncology at the University of Paris Sud in Villejuif, France.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
